Haavind advisor to Axactor in connection with co-investment partnership with Geveran.

Haavind is assisting Axactor AB (publ) with a NOK 598 million private placement of shares in order to fund Axactors Equity investment in a portfolio investment company to be established together with Geveran Trading Co. Limited, a company indirectly controlled by Mr John Fredriksen (Geveran). The investment partnership will secure EUR 300 million in investment capacity.

Kramer-Werke GmbH ("Kramer"), a subsidiary of Wacker Neuson SE, Munich, listed in the S-Dax, and John Deere GmbH & Co. KG ("John Deere"), part of at the New York exchange listed group company Deere & Company, USA, agreed on a long-term, strategic cooperation with regard to the sale of Kramer compact machines for agriculture.

For these purposes, Wacker Neuson and John Deere have agreed on an investment of John Deere in Kramer.

Clifford Chance's Moscow office has advised Pfizer on its award winning long term strategic collaboration with Russian pharmaceutical company NovaMedica.

We assisted Stadtwerke Munchen and Bayerngas in the combination of Bayerngas Norge AS and Centrica's oil and gas assets in the North Sea, establishing a new substantial oil and gas producing company with activities in Norway, the UK, Denmark and the Netherlands.

International commercial law firm Hill Dickinson has advised Juvenescence Ltd on its multimillion pound joint venture with Insilico Medicine Inc.

Juvenescence is an investment company focused on developing therapies to increase human longevity. Its principals, Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan, have extensive track records in drug development, company formation, and biotech investment. The company creates new ventures and invests directly in both startup and established longevity related companies.

Legal experts at the firm have played a pivotal role in assisting AstraZeneca and Merck & Co., Inc. formulate a global strategic oncology collaboration to develop and commercialise AstraZeneca's Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class inhibitor which is currently approved for the treatment of BRCA-mutated ovarian cancer.

GSK Stockmann advised STRENGER Gruppe comprehensively in legal and tax matters on the establishment of the real estate developer IQ INTELLIGENTES WOHNEN GmbH.

STRENGER Gruppe, headquartered in Ludwigsburg, offers services related to real estate from a single source and stands for classy freehold apartments, mature residential concepts and intelligently designed townhouses and apartments.
 

Gleiss Lutz has advised Mitsubishi Electric, a market leader for electronics and electrical engineering, on the formation of a joint venture with u-blox, the Bosch Group and Geo++. Operating under the name of SAPCORDA SERVICES GmbH, the new company will provide high-precision GNSS-based global navigation and positioning applications for the mass market.

A&O has advised Allianz Group on its joint venture with Liverpool Victoria Friendly Society to create the UK’s third largest personal insurer with over GBP1.7 billion annual premium income. The joint venture will be under the LV= brand name in the UK personal insurance market.

International law firm Clifford Chance is advising LV= on its joint venture with Allianz, creating a general insurance business with over 6 million customers. The new LV= branded joint venture will be the UK’s third largest personal insurer with over £1.7 billion annual premium income.